Expanded Access of Omidubicel for Allogeneic Transplantation in Patients With Hematological Malignancies

  • STATUS
    Recruiting
  • days left to enroll
    10
  • participants needed
    60
  • sponsor
    Gamida Cell ltd
Updated on 19 February 2024
cancer
hematologic malignancy
allogeneic transplantation
investigational treatment

Summary

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Description

Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion.

Omidubicel is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic cells from one entire unit of umbilical cord blood. Omidubicel utilizes the small molecule nicotinamide (NAM), as an epigenetic approach to inhibit differentiation and to increase the migration, bone marrow (BM) homing and engraftment efficiency of hematopoietic progenitor cells (HPC) expanded in ex vivo cultures.

The overall study objectives are to provide access to omidubicel for transplantation in patients with hematological malignancies and to collect additional safety and efficacy data.

Details
Condition Hematologic Malignancy, Blood disorder
Age 12years - 100years
Treatment omidubicel
Clinical Study IdentifierNCT04260698
SponsorGamida Cell ltd
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be at least 12 years of age
Applicable disease criteria
Patients must have one or two partially HLA-matched CBUs
Back-up stem cell source
Sufficient physiological reserves
Females of childbearing potential agree to use appropriate method of contraception
Signed written informed consent

Exclusion Criteria

Extensive bone marrow fibrosis
Donor specific anti-HLA antibodies
Pregnancy
Medically unsuitable for transplant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.